You are leaving our website

or Decline

2023 Annual Report

Annual Report 2023

Annual Report 2023 (6.3mb)

Financial highlights

182.7 £m See-through Revenue*
31.5 £m Underlying Profit Before Tax
4.55p Underlying Basic EPS
180.7 £m Statutory Revenue
-48.8 £m Reported Profit Before Tax

*Non-IFRS alternative performance measures. See-through revenue includes sales from Nizoral as if they had been invoiced by Alliance. For statutory accounting purposes the product margin on Nizoral sales is included within Revenue, in line with IFRS 15.

Results centre



We are Alliance

Download the Overview (1.2mb)

Peter Butterfield, Chief Executive Officer

CEO's Review

Record revenues in 2023, supported by investment in marketing and new product development

Download the CEO's Review (810kb)

Andrew Franklin, Chief Financial Officer

Financial Review

Robust control of the costs we can actively manage drove 5% reduction in operating costs leading to underlying EBITDA up 15% on revenue growth of 6%

Download the Financial Review (189kb)



Continuing our journey to become a more sustainable business

Download Sustainability (97kb)